This unregistered trial (n=128) was an open-label clinical series of single-dose LSD for anticipatory anxiety and pain in pre-terminal cancer patients, which demonstrated a reduction in psychological distress and improved sleep patterns.
This synthetic trial has been added to our database because a psychedelic paper (about a clinical trial) references this trial, but no (live) registration can be found.
The study involved 128 patients with metastatic malignant disease who were expected to survive for only one to two months. Participants received a single oral dose of 100 mcg of lysergic acid diethylamide (LSD) to evaluate its effects on pain intensity, affective changes, sleep patterns, and the psychological approach to death.
Results indicated a precipitous drop in pain intensity and a general lift in mood following administration. Notably, patients exhibited a striking lack of concern regarding death or other anticipatory anxieties, and many experienced improved sleep quality in the days following the intervention.
Single dose of 100 mcg lysergic acid diethylamide administered following breakfast in pre-terminal cancer patients.
Administered following breakfast; study was open-label and non-double-blind.
One-week observation period prior to LSD administration used as a baseline.